New treatment strategies in cystic fibrosis: rhDNase

Monaldi Archives for Chest Disease

Volumn 51, Issue 2, 1996, Pages 125-129

  Shah, P L ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; rhDNase

Indexed keywords

DNA; DORNASE ALFA; ESTERASE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA CONTENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; SPUTUM; UNITED KINGDOM; UNITED STATES; VISCOELASTICITY;

EID: 0030006771     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Lethem MI, James SL, Marriott C, Burke JF. - The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 1990; 3: 19-23.
2. Chernick WS, Barbero GJ. - Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Paediatrics 1959; 24: 739-745.